Skip to main content

Women Versus Men: Is There Equal Benefit and Safety from Statins?

Abstract

Coronary heart disease (CHD) is the leading cause of death in the United States. CHD risk differs between genders, with coronary events lagging behind ten years for women in comparison to men. Low-density lipoprotein cholesterol lowering with statin therapy is a major target for cardiovascular risk reduction. The benefit of statin therapy has been well established in men, for both primary and secondary prevention. However, the same has not been shown for women. While studies have demonstrated benefit in women for secondary prevention, their role in primary prevention of cardiovascular disease remains controversial. Data released over the past several years regarding statin efficacy and safety in men and women has been inconsistent, given that these studies had small sample sizes with numerous study limitations. A recent large scale meta-analysis of both primary and secondary statin prevention trials with sex-specific outcomes demonstrated a similar benefit in both men and women. Statins demonstrated a decrease in cardiovascular events and all-cause mortality in both sexes. In regards to statin safety, additional trials investigating the difference in adverse events of statins in men versus women, particularly new onset of diabetes, myalgias, and liver dysfunction, are warranted. Increased awareness and monitoring of female patients for myalgias and hyperglycemia should be considered as a precaution. Overall, women need to be better represented in prospective clinical trials powered to evaluate gender-specific differences in statin safety and efficacy in the management of cardiovascular disease.

This is a preview of subscription content, access via your institution.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.•

    Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update. Circulation. 2015;131:e29–e222. highlights importance of risk reduction in statin therapy.

    Article  PubMed  Google Scholar 

  2. 2.

    Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Yusuf S, Reddy, Ounpuu S, Anand S. Global burden of cardiovascular disease: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Kappert K, Bohm M, Schmeider R, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012;126(8):934.

    Article  PubMed  Google Scholar 

  5. 5.

    Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160:339–343.

  6. 6.••

    Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomized trials. Lancet. 2015;385:1397–405. this meta-analysis supports our conclusion of a similar benefit in both men and women in both primary and secondary statin prevention trials.

    Article  Google Scholar 

  7. 7.

    Dale KM, Coleman CI, Shah SA, et al. Impact of gender on statin efficacy. Curr Med Res Opin. 2007;23:565–74.

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Mombelli G, Bosisio R, Calabresi L, et al. Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. J Clin Lipidol. 2015;9:226–33.

    Article  PubMed  Google Scholar 

  9. 9.

    Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, et al. Gender differences in short-term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function. Nutr Metab Cardiovasc Dis. 2008;18(3):182–8.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Nishi K, Uno M, Fukuzawa K, Horiguchi H, Shinno K, Nagahiro S. Clinicopathological significance of lipid peroxidation in carotid plaques. Atherosclerosis. 2002;160:289–96.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Nakajima K. Sex-related differences in response of plasma lipids to simvastatin: the Saitama Postmenopausal Lipid Intervention Study. S-POLIS Group. Clin Ther. 1999;21(12):2047–57.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Bukkapatnam R, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol. 2010;13:84–90.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol. 2010;138(1):25–31.

    Article  PubMed  Google Scholar 

  14. 14.

    Gutierrez J, Ramirez G, Rundek T, et al. Statin therapy in the prevention of recurrent cardiovascular events. Arch Intern Med. 2012;172(12):909–19.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572–82.

    Article  CAS  PubMed  Google Scholar 

  16. 16.

    Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, et al. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006;37(6):1427–31.

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Heart Protection Study Collaborative Group. Effects of cholesterol lowering with simvastatin on stroke and other major vascular event sin 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–67.

    Article  Google Scholar 

  18. 18.

    Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol And Recurrent Events (CARE) study. Circulation. 1999;99:216–23.

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.

    Article  Google Scholar 

  20. 20.

    Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008;39(9):2444–8.

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    Mosca L. Sex, statins, and statistics. Lancet. 2015;385:1368–9.

    Article  PubMed  Google Scholar 

  22. 21.•

    Pencina MJ, Navar-Boggan A, D’Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422–31. Highlights adult eligiblility for statin therapy.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Roda Plakogiannis.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Statin Drugs

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Plakogiannis, R., Arif, S.A. Women Versus Men: Is There Equal Benefit and Safety from Statins?. Curr Atheroscler Rep 18, 6 (2016). https://doi.org/10.1007/s11883-016-0562-9

Download citation

Keywords

  • HMG-CoA reductase inhibitors
  • Statins
  • Gender
  • Lipid profile
  • Cardiovascular disease